PRKD1 and prostate cancer: In the allografted subcutaneous RM1 mouse model for prostate cancer, treating mice with specific PKD inhibitor CRT0066101 resulted in a decreased mast cell recruitment and showed no gain in tumor size or cancer progression such as angiogenesis [52].